Navis Wealth Advisors LLC Cuts Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Navis Wealth Advisors LLC reduced its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 11.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,120 shares of the biopharmaceutical company’s stock after selling 150 shares during the quarter. Regeneron Pharmaceuticals accounts for 1.3% of Navis Wealth Advisors LLC’s portfolio, making the stock its 15th biggest holding. Navis Wealth Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $984,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of REGN. Annis Gardner Whiting Capital Advisors LLC bought a new position in shares of Regeneron Pharmaceuticals during the third quarter valued at $26,000. Fortitude Family Office LLC bought a new position in Regeneron Pharmaceuticals in the fourth quarter valued at about $31,000. MCF Advisors LLC lifted its holdings in Regeneron Pharmaceuticals by 50.0% in the fourth quarter. MCF Advisors LLC now owns 36 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 12 shares during the period. Criterion Capital Advisors LLC bought a new position in Regeneron Pharmaceuticals in the fourth quarter valued at about $37,000. Finally, Sutton Wealth Advisors Inc. lifted its holdings in Regeneron Pharmaceuticals by 38.2% in the third quarter. Sutton Wealth Advisors Inc. now owns 47 shares of the biopharmaceutical company’s stock valued at $39,000 after acquiring an additional 13 shares during the period. 83.31% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals Price Performance

NASDAQ REGN traded down $7.48 during trading on Friday, hitting $883.20. 505,652 shares of the stock traded hands, compared to its average volume of 431,865. The company has a market capitalization of $96.94 billion, a P/E ratio of 25.42, a price-to-earnings-growth ratio of 2.54 and a beta of 0.11. The firm has a 50-day simple moving average of $948.00 and a 200-day simple moving average of $894.04. The company has a quick ratio of 4.94, a current ratio of 5.69 and a debt-to-equity ratio of 0.10. Regeneron Pharmaceuticals, Inc. has a 12-month low of $684.80 and a 12-month high of $998.33.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share for the quarter, beating the consensus estimate of $10.73 by $1.13. The business had revenue of $3.43 billion during the quarter, compared to analysts’ expectations of $3.29 billion. Regeneron Pharmaceuticals had a return on equity of 17.61% and a net margin of 30.14%. The firm’s revenue for the quarter was up .6% compared to the same quarter last year. During the same quarter last year, the business posted $10.96 EPS. As a group, analysts predict that Regeneron Pharmaceuticals, Inc. will post 38.8 EPS for the current year.

Analyst Upgrades and Downgrades

REGN has been the topic of a number of recent research reports. Cantor Fitzgerald reissued a “neutral” rating and issued a $925.00 target price on shares of Regeneron Pharmaceuticals in a report on Monday, April 15th. BMO Capital Markets upped their price target on Regeneron Pharmaceuticals from $1,055.00 to $1,082.00 and gave the stock an “outperform” rating in a research report on Monday, February 5th. Bank of America upped their price target on Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the stock an “underperform” rating in a research report on Friday, April 12th. Barclays upped their price target on Regeneron Pharmaceuticals from $935.00 to $1,020.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 23rd. Finally, Morgan Stanley upped their price target on Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 13th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and sixteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $977.77.

Insider Activity

In other news, EVP Andrew J. Murphy sold 5,783 shares of the firm’s stock in a transaction that occurred on Thursday, March 14th. The stock was sold at an average price of $956.47, for a total value of $5,531,266.01. Following the completion of the sale, the executive vice president now directly owns 48,306 shares of the company’s stock, valued at approximately $46,203,239.82. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, Director Arthur F. Ryan sold 100 shares of the firm’s stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $954.22, for a total transaction of $95,422.00. Following the completion of the sale, the director now directly owns 18,382 shares of the company’s stock, valued at approximately $17,540,472.04. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Andrew J. Murphy sold 5,783 shares of the firm’s stock in a transaction that occurred on Thursday, March 14th. The stock was sold at an average price of $956.47, for a total value of $5,531,266.01. Following the sale, the executive vice president now directly owns 48,306 shares of the company’s stock, valued at $46,203,239.82. The disclosure for this sale can be found here. Insiders sold 11,022 shares of company stock valued at $10,552,991 in the last ninety days. Insiders own 8.83% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.